July 2007 With the help of Caliper Lifesciences, Inc. Longmed has retained a demonstration unit of Xenogen IVIS Lumina. We have set it up in several places including Chinese Academy of Sciences, Chinese Medical Academy of Science, Crownbio, Fudan University, and Nanjing Model Animal Institution, etc… One of our potential customers have also done several comparative experiments between Lumina and another competitive technology, and Xenogen technology has show its clear advantage over other competitive technology. Please see details on the experimental results.

March 2007 With the help of Nanjing Model Animal Institiution, Longmed has imported three lines of LPTA (Light Producing Transgenic Animals) into China. They are NFkB-Luc, VEGFr2-luc, and TNF-alfa-luc. Those are important transgenic animal lines for research toward inflammation, angiogenesis, immunology, and drug discovery. Several research laboratories around the nation have already purchased these LPTA for their research. For detail information about those animals and their availability, please contact info@longmed.com for further information.

May 2007 Caliper announced during last AACR meeting in LA that five drugs were approved by FDA using Xenogen in vivo imaging technology. Those achievements have demonstrated the power of Xenogen IVIS technology toward drug discovery and research. Since Caliper has the patent of this methodology: Detection of substance labeled by visible light inside mamal (CN95198006.8), using Xenogen technology for your drug discovery research is the only way for your discovery result to be accepted by any commercial entity worldwide.

June 2007 INSTITUTE OF MEDICINAL BIOTECHNOLOGY, part of CHINESE ACADEMY OF MEDICAL SCIENCES has just signed an agreement with Longmed to purchase an IVIS200 from Caliper Lifescience. IVIS200 can enable they to visualize the labled celllines and virus inside small animal in 3 dimention and obtain the 3D image. This unit will be used toward their research in Oncology, Virology, and drug discovery, etc… Obtaining the state-of-art technology from Xenogen have shown that the research and technical capability of Institute of Medical Biotechnology has advanced to a brand new level.

The Price Wales Hospital of the Chinese University of Hong Kong has purchased an IVIS100 system for its biomedical research. The areas that they are interested in are Oncology, Gene Therapy, Immunology, and Infection disease. This unit will be the first unit from Xenogen to install in Hong Kong, and the first unit of IVIS100 in China as well. (November, 2005)

Xenogen established its technology certificate program for the international distributors, and hosted its first engineer training program in Alameda, California in August 2005. Our engineer, Henry Dong, attended this week-long training and was certified as the only preferred service engineer for Xenogen product in China. He also visited headquarter office of Visualsonics in Toronto, Canada and was trained with Vevo system during this trip. (September 2005)

Xenogen has released its 3-D capability for its IVIS200 instrument. It is truly a state-of-art technology and represents a milestone for optical small animal in vivo imaging. As part of the service, Longmed helped CK-Lifesciences installed the 3-D capability software to its IVIS200 instrument. (September 2005)

Zensun, Inc. (www.zensun.com）located in Zhang-Jiang High Tech Park, Shanghai becomes the first customer for Visualsonics Vevo system. Visualsonics, Inc. (www.visualsonics.com) located in Toronto Canada, is the only firm in the world manufacturing the bio-microscopic ultrasound instrument for small animal in vivo imaging. This bio-microscopy ultrasound system, Vevo, produces ultrasound with frequency from 35 to 85Hz, vs. human ultrasound of 5-15Hz. It enables researchers to visualize animal in vivo structure with a resolution of 30 um，much higher than the 1mm resolution with a human ultrasound. Zensun will leverage this technology toward its cardiology and oncology drug development effort and make this instrument an integrated part for its animal research facility in Shanghai, China. (July 2005)

On January 31, 2005, CK-Lifesciences has signed an agreement with Longmed to purchase an IVIS 200 system from Xenogen for Bioluminescence imaging technology for in vivo small animal research. The system is scheduled to be installed toward the end of February in Beijing Research Institute of CK-Lifesciences. This will be the first unit installed in Asia (ex-Japan), and it symbolizes the advance level of biomedical research conducted by CK-Lifesciences and another business success by Longmed, Inc. IVIS 200 is the latest member of Xenogen in vivo imaging family, it symbolize one of the best technologies in biomedical research and the highest degree of latest scientific advancement.

September 28th, Shanghai Genomics has installed the second unit of IVIS system, and has obtained satisfactory results from its testing experiments.(picture)

July 15th, Longmed has signed its first customers in China with National Center for Biomedical Research in Beijing. It will be the very first IVIS (In Vivo Imaging System) from Xenogen in China. System is scheduled for installation around end of August 2004(picture).

June 26th, Executives and Scientists from Xenogen have visited potential customers in China and expressed very optimistic outlook for Chinese market.

June 15th, Longmed was selected as one of the VIP Ventures founded by Oversea Returnee and was awarded with Fellowship Fund by National Science Foundation.

May 5th, Longmed was awarded with High-Tech Venture status by National Science Committee in Zhong Guan Cun, the reputable Silican Valley in China.

March 31st, 2004, Dr. Adam C. Zhao gave a lecture at Medical Research Institute of Tsinghua University, titled "Current Development in Life Science In Vivo Imaging Technologies"